Connection
Michael Szarek to Prognosis
This is a "connection" page, showing publications Michael Szarek has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.055 |
|
|
|
-
Jukema JW, Van Neer NJ, Szarek M, Cobbaert C, Bittner VA, Schwertfeger M, Bhatt DL, Fazio S, Goodman SG, Harrington RA, Stevanovic I, White HD, Steg PG, Schwartz GG. Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. Eur Heart J. 2026 Oct 26; 47(40):6008-6017.
Score: 0.033
-
Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct; 28(10):2508-13.
Score: 0.008
-
Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005 Sep; 125(3):526-31.
Score: 0.008
-
Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005 May; 26(9):890-6.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|